Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application ...
Add Yahoo as a preferred source to see more of our stories on Google. BrainIAC, a new AI model, analyzes brain MRIs to predict dementia risk, tumor mutations, and brain cancer survival. (CREDIT: ...
Stocktwits on MSN
TLX stock surges overnight after FDA agrees to review brain cancer imaging agent application
The NDA application was resubmitted to the U.S. FDA for approval, and the company expects the PDUFA goal date of September 11, 2026. ・The TLX101-Px(Pixclara) approval will help in the treatment of ...
A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers after their primary treatment, and was published in the journal ...
Telix Pharmaceuticals shares (ASX: TLX) jumped 7% to $14.60 into the weekend, leading a broader rally in medical technology stocks on the ASX 200, after the US Food and Drug Administration formally ...
Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYDNEY, April 16, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, ...
Vietnam Investment Review on MSN
FDA accepts Telix brain cancer imaging drug application
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug ...
FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. While rare, malignant brain tumors often have poor outcomes Nearly half of all malignant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results